NEWS

  • October, 21 2015
  • PeptiMed™ US Patent Application No. 13/113,963 was issued a Notice of Allowance.

  • March 7, 2016
  • PeptiMed™ Chinese Patent Application No. 201180059699.3 was issued a Notice of Allowance.

  • May 23 2016
  • PeptiMed™ receives orphan designation from the Food and Drug Administration for its lead candidate PEP0101 in treatment of all types of ovarian cancer.

  • October 20, 2016
  • PeptiMed™ Japanese Patent Application No. 2013-511417 was issued a Notice of Allowance.

  • October 21, 2016
  • PeptiMed™ European Patent Application No. 11722271.1 was issued a Notice of Allowance.

  • December 22, 2016
  • PeptiMed™ Australian Patent Application No. 2011255203 was issued a Notice of Allowance.

UPCOMING EVENTS

  • May 17-18, 2017
  • PeptiMed™ will attend the MedCity INVEST Conference in Chicago, Illinois http://events.medcitynews.com/invest/

  • June 1, 2017
  • PeptiMed™ will host its annual shareholder meeting at 6:30pm at 6:30 pm, La Quinta Inn and Suites, Bannockburn, Illinois.

  • June 2, 2017
  • PeptiMed™ will present is business case at the 3rd Annual Immuno-Oncology BD&L and Investment Forum in Chicago, Illinois.

  • June 2-6, 2017
  • PeptiMed™ will attend the American Society of Oncology Annual Meeting in Chicago, Illinois. http://am.asco.org

  • June 19-22, 2017
  • PeptiMed™ will participate in the Biopartnering sessions at the Annual BIO Conference in San Diego, California. http://convention.bio.org

PUBLICATIONS

  • AACR Abstract 2014.
  • Abstract LB-103: L1CAM-targeted delivery of siRNA using elastin-like polypeptide (ELP) nanoparticles inhibits the growth of human tumors implanted in mice Abstract URL Link


  • AACR Abstract 2015.
  • Specific delivery of immunostimulatory RNA via nanoparticles blocks growth of primary and disseminated ovarian tumors Abstract URL Link